WT
KRTX

Wellcome Trust’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Wellcome Trust’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,266,376
Closed -$95M – 24
2019
Q4 		$95M Hold
1,266,376
– – 1.27% 18
2019
Q3 		$20.6M Buy
+1,266,376
New +$24.6M 0.33% 18

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wellcome Trust's KRTX Position: Q1 2020 in Review

Wellcome Trust sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2020, closing a stake of 1,266,376 shares — an estimated $95M sold.

Wellcome Trust first reported a position in KRTX in Q3 2019 and held it in 2 quarters. The position peaked at $95M in Q4 2019. 99 funds tracked by Wall St. Rank hold KRTX as of Q1 2020.

  • Wellcome Trust reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Wellcome Trust sold 1,266,376 Karuna Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $95M.
  • Wellcome Trust first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2019 and held it in 2 quarters.
  • Wellcome Trust's Karuna Therapeutics, Inc. Common Stock position peaked at $95M in Q4 2019.
  • 99 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Wellcome Trust's 13F filing for Q1 2020, filed 17 Apr 2020.